Antibiotics (Basel, Switzerland) · 2026
Enhanced In Vitro Stability of Bedaquiline with Ascorbic Acid and Pyruvate During Long-Term Incubation in Mycobacterium Species.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Batista Sara, Lamata Jordi, Feliu Lidia, Planas Marta, Fernandez-Pittol Mariana, Martinez Diego, San Nicolás Lorena, Tudó Griselda, Gonzalez-Martin Julian
Аннотация
BACKGROUND: Drug susceptibility testing in Mycobacterium species typically requires prolonged incubation periods during which the chemical integrity of antibiotics may not be maintained, potentially compromising the reliability and accuracy of minimum inhibitory concentration (MIC) determinations.
OBJECTIVES: This study evaluated the in vitro stability of several antibiotics, including recently introduced agents (bedaquiline [BDQ], pretomanid, delamanid and clofazimine) used for treating multidrug-resistant mycobacteriosis (linezolid and moxifloxacin), and those commonly included in combination regimens (rifampicin, isoniazid, ethambutol and clarithromycin).
METHODS: Antibiotics were pre-incubated at 37 °C before MIC determination and those exhibiting two or more dilutions in MIC were further tested in combination with ascorbic acid (AA) and pyruvate (P).
RESULTS: All antibiotics demonstrated stability except BDQ, which showed significant MIC variation after pre-incubation, which was prevented when BDQ was combined with AA and P.
CONCLUSIONS: These findings suggest that the combined use of AA and P may serve as an effective stabilizing strategy for BDQ during MIC determination.
OBJECTIVES: This study evaluated the in vitro stability of several antibiotics, including recently introduced agents (bedaquiline [BDQ], pretomanid, delamanid and clofazimine) used for treating multidrug-resistant mycobacteriosis (linezolid and moxifloxacin), and those commonly included in combination regimens (rifampicin, isoniazid, ethambutol and clarithromycin).
METHODS: Antibiotics were pre-incubated at 37 °C before MIC determination and those exhibiting two or more dilutions in MIC were further tested in combination with ascorbic acid (AA) and pyruvate (P).
RESULTS: All antibiotics demonstrated stability except BDQ, which showed significant MIC variation after pre-incubation, which was prevented when BDQ was combined with AA and P.
CONCLUSIONS: These findings suggest that the combined use of AA and P may serve as an effective stabilizing strategy for BDQ during MIC determination.